These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 22331081)

  • 1. Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy.
    Rigamonti N; Bellone M
    Cancer Immunol Immunother; 2012 Apr; 61(4):453-68. PubMed ID: 22331081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The new aspects of immunotherapy in prostate cancer.
    Ghanei M; Shohrati M; Saburi A
    Cancer Immunol Immunother; 2012 Dec; 61(12):2375-6. PubMed ID: 22736256
    [No Abstract]   [Full Text] [Related]  

  • 3. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin D-binding protein-derived macrophage-activating factor, GcMAF, and prostate cancer.
    Bellone M; Rigamonti N
    Cancer Immunol Immunother; 2012 Dec; 61(12):2377-8. PubMed ID: 22740161
    [No Abstract]   [Full Text] [Related]  

  • 5. Spontaneous adenocarcinoma mouse models for immunotherapy.
    Gendler SJ; Mukherjee P
    Trends Mol Med; 2001 Oct; 7(10):471-5. PubMed ID: 11597523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for prostate cancer: walk, don't run.
    Drake CG
    J Clin Oncol; 2009 Sep; 27(25):4035-7. PubMed ID: 19635998
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevention of human PC-346C prostate cancer growth in mice by a xenogeneic tissue vaccine.
    Suckow MA; Rosen ED; Wolter WR; Sailes V; Jeffrey R; Tenniswood M
    Cancer Immunol Immunother; 2007 Aug; 56(8):1275-83. PubMed ID: 17242926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer.
    Aragon-Ching JB; Williams KM; Gulley JL
    Front Biosci; 2007 Sep; 12():4957-71. PubMed ID: 17569623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current immunotherapeutic strategies in prostate cancer.
    Grosso JF; Drake CG
    Surg Oncol Clin N Am; 2007 Oct; 16(4):861-71, x. PubMed ID: 18022549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic prostate cancer vaccines: a review of the latest developments.
    Mohebtash M; Madan RA; Gulley JL; Arlen PM
    Curr Opin Investig Drugs; 2008 Dec; 9(12):1296-301. PubMed ID: 19037836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined treatment effects of radiation and immunotherapy: studies in an autochthonous prostate cancer model.
    Wada S; Harris TJ; Tryggestad E; Yoshimura K; Zeng J; Yen HR; Getnet D; Grosso JF; Bruno TC; De Marzo AM; Netto GJ; Pardoll DM; DeWeese TL; Wong J; Drake CG
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):769-76. PubMed ID: 24064321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for Prostate Cancer: Where Do We Go From Here?-PART 1: Prostate Cancer Vaccines.
    Patel A; Fong L
    Oncology (Williston Park); 2018 Mar; 32(3):112-20. PubMed ID: 29548065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-Talk between Myeloid-Derived Suppressor Cells and Mast Cells Mediates Tumor-Specific Immunosuppression in Prostate Cancer.
    Jachetti E; Cancila V; Rigoni A; Bongiovanni L; Cappetti B; Belmonte B; Enriquez C; Casalini P; Ostano P; Frossi B; Sangaletti S; Chiodoni C; Chiorino G; Pucillo CE; Tripodo C; Colombo MP
    Cancer Immunol Res; 2018 May; 6(5):552-565. PubMed ID: 29523597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer immunotherapy.
    May KF; Gulley JL; Drake CG; Dranoff G; Kantoff PW
    Clin Cancer Res; 2011 Aug; 17(16):5233-8. PubMed ID: 21700764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical development of immunotherapy for prostate cancer.
    Noguchi M; Koga N; Igawa T; Itoh K
    Int J Urol; 2017 Sep; 24(9):675-680. PubMed ID: 28636142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mathematical Prostate Cancer Evolution: Effect of Immunotherapy Based on Controlled Vaccination Strategy.
    Ba Dziul D; Jakubczyk P; Chotorlishvili L; Toklikishvilie Z; Traciak J; Jakubowicz-Gil J; Chmiel-Szajner S
    Comput Math Methods Med; 2020; 2020():7970265. PubMed ID: 32411286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mouse model of prostate cancer.
    Liu Z; Eltoum IE; Guo B; Beck BH; Cloud GA; Lopez RD
    J Immunol; 2008 May; 180(9):6044-53. PubMed ID: 18424725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor-antigens and immune landscapes identification for prostate adenocarcinoma mRNA vaccine.
    Zheng X; Xu H; Yi X; Zhang T; Wei Q; Li H; Ai J
    Mol Cancer; 2021 Dec; 20(1):160. PubMed ID: 34872584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic-cell vaccination for prostate cancer.
    Thomas-Kaskel AK; Veelken H
    Immunotherapy; 2009 Jan; 1(1):63-72. PubMed ID: 20635974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer as a model for tumour immunotherapy.
    Drake CG
    Nat Rev Immunol; 2010 Aug; 10(8):580-93. PubMed ID: 20651745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.